AbbVie Inc. (ABBV) announced on Friday that it has entered into an agreement to acquire Nimble Therapeutics. The transaction involves a cash payment of $200 million at closing, supplemented by certain interim funding and milestone payments.
Through this acquisition, AbbVie will gain Nimble's leading asset, a pipeline of other novel oral peptide candidates, as well as access to its peptide synthesis, screening, and optimization platform.
AbbVie anticipates that this strategic acquisition will bolster its immunology pipeline and open up further growth opportunities.
At present, AbbVie's stock is valued at $173.83 on the New York Stock Exchange, reflecting a 0.42 percent increase.
The material has been provided by InstaForex Company - www.instaforex.com
Through this acquisition, AbbVie will gain Nimble's leading asset, a pipeline of other novel oral peptide candidates, as well as access to its peptide synthesis, screening, and optimization platform.
AbbVie anticipates that this strategic acquisition will bolster its immunology pipeline and open up further growth opportunities.
At present, AbbVie's stock is valued at $173.83 on the New York Stock Exchange, reflecting a 0.42 percent increase.
The material has been provided by InstaForex Company - www.instaforex.com